Public Profile

Mylan S.p.A.

Mylan S.p.A., a prominent player in the global pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and other key regions. Founded in 1961, Mylan has established itself as a leader in generic and specialty medications, focusing on improving access to high-quality healthcare solutions. The company offers a diverse portfolio of products, including generic drugs, over-the-counter medications, and complex generics, which are distinguished by their affordability and efficacy. Mylan's commitment to innovation and quality has earned it a strong market position, with notable achievements in expanding access to essential medicines worldwide. With a focus on patient-centric solutions, Mylan continues to play a vital role in the healthcare landscape, striving to meet the evolving needs of patients and healthcare providers alike.

DitchCarbon Score

How does Mylan S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

32

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Mylan S.p.A.'s score of 32 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.

46%

Let us know if this data was useful to you

Mylan S.p.A.'s reported carbon emissions

Mylan S.p.A., headquartered in Italy, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing greenhouse gas emissions. Mylan's commitment to addressing climate change may align with broader industry trends, which often include initiatives aimed at improving energy efficiency, reducing waste, and transitioning to renewable energy sources. As the company progresses in its sustainability journey, further information on their climate strategies and emissions data may become available.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Mylan S.p.A.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Mylan S.p.A. is in IT, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Mylan S.p.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Teva Pharmaceutical Fine Chemicals S.r.l

IT
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

STADA Arzneimittel Aktiengesellschaft

DE
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Diocle S.p.A.

IT
Real estate services (70)
Updated about 3 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers